journal
https://read.qxmd.com/read/34310904/survival-outcomes-in-older-men-with-non-metastatic-castration-resistant-prostate-cancer-treated-with-androgen-receptor-inhibitors-a-us-food-and-drug-administration-pooled-analysis-of-patient-level-data-from-three-randomised-trials
#1
Jaleh Fallah, Lijun Zhang, Anup Amatya, Yutao Gong, Bellinda King-Kallimanis, Vishal Bhatnagar, Chana Weinstock, Daniel L Suzman, Sundeep Agrawal, Elaine Chang, Mitchell S Anscher, Dow-Chung Chi, James X Xu, Jamie R Brewer, Michael H Brave, Mehrnoosh Hadadi, Marc R Theoret, Paul G Kluetz, Kirsten B Goldberg, Amna Ibrahim, Shenghui Tang, Richard Pazdur, Julia A Beaver, Laleh Amiri-Kordestani, Harpreet Singh
BACKGROUND: Little is known about the benefit-risk profile of second-generation androgen receptor inhibitors in older men with non-metastatic castration-resistant prostate cancer. We aimed to examine the efficacy and safety of second-generation androgen receptor inhibitors in men aged 80 years or older with non-metastatic castration-resistant prostate cancer. METHODS: We searched for all randomised controlled clinical trials evaluating second-generation androgen receptor inhibitors in patients with non-metastatic castration-resistant prostate cancer submitted to the US Food and Drug Administration before Aug 15, 2020, and pooled data from three trials that met the selection criteria...
July 23, 2021: Lancet Oncology
https://read.qxmd.com/read/34274045/uk-government-urged-to-prioritise-improvements-to-nhs-imaging-services
#2
Talha Khan Burki
No abstract text is available yet for this article.
July 15, 2021: Lancet Oncology
https://read.qxmd.com/read/34270925/alcohol-and-the-global-burden-of-cancer-what-are-we-missing
#3
Amy C Justice
No abstract text is available yet for this article.
July 13, 2021: Lancet Oncology
https://read.qxmd.com/read/34270924/global-burden-of-cancer-in-2020-attributable-to-alcohol-consumption-a-population-based-study
#4
Harriet Rumgay, Kevin Shield, Hadrien Charvat, Pietro Ferrari, Bundit Sornpaisarn, Isidore Obot, Farhad Islami, Valery E P P Lemmens, Jürgen Rehm, Isabelle Soerjomataram
BACKGROUND: Alcohol use is causally linked to multiple cancers. We present global, regional, and national estimates of alcohol-attributable cancer burden in 2020 to inform alcohol policy and cancer control across different settings globally. METHODS: In this population-based study, population attributable fractions (PAFs) calculated using a theoretical minimum-risk exposure of lifetime abstention and 2010 alcohol consumption estimates from the Global Information System on Alcohol and Health (assuming a 10-year latency period between alcohol consumption and cancer diagnosis), combined with corresponding relative risk estimates from systematic literature reviews as part of the WCRF Continuous Update Project, were applied to cancer incidence data from GLOBOCAN 2020 to estimate new cancer cases attributable to alcohol...
July 13, 2021: Lancet Oncology
https://read.qxmd.com/read/34252375/clinical-and-molecular-characteristics-of-her2-low-positive-breast-cancer-pooled-analysis-of-individual-patient-data-from-four-prospective-neoadjuvant-clinical-trials
#5
Carsten Denkert, Fenja Seither, Andreas Schneeweiss, Theresa Link, Jens-Uwe Blohmer, Marianne Just, Pauline Wimberger, Almuth Forberger, Hans Tesch, Christian Jackisch, Sabine Schmatloch, Mattea Reinisch, Erich F Solomayer, Wolfgang D Schmitt, Claus Hanusch, Peter A Fasching, Kristina Lübbe, Christine Solbach, Jens Huober, Kerstin Rhiem, Frederik Marmé, Toralf Reimer, Marcus Schmidt, Bruno V Sinn, Wolfgang Janni, Elmar Stickeler, Laura Michel, Oliver Stötzer, Eric Hahnen, Jenny Furlanetto, Sabine Seiler, Valentina Nekljudova, Michael Untch, Sibylle Loibl
BACKGROUND: The development of anti-HER2 antibody-drug conjugates opens new therapeutic options for patients with breast cancer, including patients with low expression of HER2. To characterise this new breast cancer subtype, we have compared the clinical and molecular characteristics of HER2-low-positive and HER2-zero breast cancer, including response to neoadjuvant chemotherapy and prognosis. METHODS: In this pooled analysis of individual patient data, we evaluated a cohort of 2310 patients with HER2-non-amplified primary breast cancer that were treated with neoadjuvant combination chemotherapy in four prospective neoadjuvant clinical trials (GeparSepto, NCT01583426; GeparOcto, NCT02125344; GeparX, NCT02682693; Gain-2 neoadjuvant, NCT01690702) between July 30, 2012, and March 20, 2019...
July 9, 2021: Lancet Oncology
https://read.qxmd.com/read/34252374/perioperative-or-postoperative-adjuvant-oxaliplatin-with-s-1-versus-adjuvant-oxaliplatin-with-capecitabine-in-patients-with-locally-advanced-gastric-or-gastro-oesophageal-junction-adenocarcinoma-undergoing-d2-gastrectomy-resolve-an-open-label-superiority-and
#6
Xiaotian Zhang, Han Liang, Ziyu Li, Yingwei Xue, Yanong Wang, Zhiwei Zhou, Jiren Yu, Zhaode Bu, Lin Chen, Yian Du, Xinbao Wang, Aiwen Wu, Guoli Li, Xiangqian Su, Gang Xiao, Ming Cui, Dan Wu, Li Chen, Xiaojiang Wu, Yanbing Zhou, Lianhai Zhang, Chengxue Dang, Yulong He, Zhongtao Zhang, Yihong Sun, Yong Li, Huanqiu Chen, Yuxian Bai, Changsong Qi, Peiwu Yu, Guanbao Zhu, Jian Suo, Baoqing Jia, Leping Li, Changming Huang, Fei Li, Yingjiang Ye, Huimian Xu, Xin Wang, Yannan Yuan, Jian-Yu E, Xiangji Ying, Chen Yao, Lin Shen, Jiafu Ji
BACKGROUND: The optimal perioperative chemotherapeutic regimen for locally advanced gastric cancer remains undefined. We evaluated the efficacy and safety of perioperative and postoperative S-1 and oxaliplatin (SOX) compared with postoperative capecitabine and oxaliplatin (CapOx) in patients with locally advanced gastric cancer undergoing D2 gastrectomy. METHODS: We did this open-label, phase 3, superiority and non-inferiority, randomised trial at 27 hospitals in China...
July 9, 2021: Lancet Oncology
https://read.qxmd.com/read/34252373/her2-a-never-ending-story
#7
Maria Vittoria Dieci, Federica Miglietta
No abstract text is available yet for this article.
July 9, 2021: Lancet Oncology
https://read.qxmd.com/read/34246331/lebanon-faces-critical-shortage-of-drugs
#8
Manjulika Das
No abstract text is available yet for this article.
July 8, 2021: Lancet Oncology
https://read.qxmd.com/read/34246330/new-radiation-health-standard-required-for-deep-space-travel
#9
Elizabeth Gourd
No abstract text is available yet for this article.
July 8, 2021: Lancet Oncology
https://read.qxmd.com/read/34246329/esmo-world-congress-on-gastrointestinal-cancer-2021
#10
Katherine Gourd
No abstract text is available yet for this article.
July 8, 2021: Lancet Oncology
https://read.qxmd.com/read/34246328/nomograms-to-predict-outcomes-after-177-lu-psma-therapy-in-men-with-metastatic-castration-resistant-prostate-cancer-an-international-multicentre-retrospective-study
#11
Andrei Gafita, Jeremie Calais, Tristan R Grogan, Boris Hadaschik, Hui Wang, Manuel Weber, Shahneen Sandhu, Clemens Kratochwil, Rouzbeh Esfandiari, Robert Tauber, Anna Zeldin, Hendrik Rathke, Wesley R Armstrong, Andrew Robertson, Pan Thin, Calogero D'Alessandria, Matthew B Rettig, Ebrahim S Delpassand, Uwe Haberkorn, David Elashoff, Ken Herrmann, Johannes Czernin, Michael S Hofman, Wolfgang P Fendler, Matthias Eiber
BACKGROUND: Lutetium-177 (177 Lu) prostate-specific membrane antigen (177 Lu-PSMA) is a novel targeted treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). Predictors of outcomes after 177 Lu-PSMA to enhance its clinical implementation are yet to be identified. We aimed to develop nomograms to predict outcomes after 177 Lu-PSMA in patients with mCRPC. METHODS: In this multicentre, retrospective study, we screened patients with mCRPC who had received 177 Lu-PSMA between Dec 10, 2014, and July 19, 2019, as part of the previous phase 2 trials (NCT03042312, ACTRN12615000912583) or compassionate access programmes at six hospitals and academic centres in Germany, the USA, and Australia...
July 8, 2021: Lancet Oncology
https://read.qxmd.com/read/34246327/serbia-faces-bleak-cancer-situation
#12
Manjulika Das
No abstract text is available yet for this article.
July 8, 2021: Lancet Oncology
https://read.qxmd.com/read/34242575/correction-to-lancet-oncol-2021-published-online-july-1-https-doi-org-10-1016-s1470-2045-21-00389-2
#13
(no author information available yet)
No abstract text is available yet for this article.
July 6, 2021: Lancet Oncology
https://read.qxmd.com/read/34237250/cabozantinib-for-radioiodine-refractory-differentiated-thyroid-cancer-cosmic-311-a-randomised-double-blind-placebo-controlled-phase-3-trial
#14
Marcia S Brose, Bruce Robinson, Steven I Sherman, Jolanta Krajewska, Chia-Chi Lin, Fernanda Vaisman, Ana O Hoff, Erika Hitre, Daniel W Bowles, Jorge Hernando, Leonardo Faoro, Kamalika Banerjee, Jennifer W Oliver, Bhumsuk Keam, Jaume Capdevila
BACKGROUND: Patients with radioiodine-refractory differentiated thyroid cancer (DTC) previously treated with vascular endothelial growth factor receptor (VEGFR)-targeted therapy have aggressive disease and no available standard of care. The aim of this study was to evaluate the tyrosine kinase inhibitor cabozantinib in this patient population. METHODS: In this global, randomised, double-blind, placebo-controlled, phase 3 trial, patients aged 16 years and older with radioiodine-refractory DTC (papillary or follicular and their variants) and an Eastern Cooperative Oncology Group performance status of 0 or 1 were randomly assigned (2:1) to oral cabozantinib (60 mg once daily) or matching placebo, stratified by previous lenvatinib treatment and age...
July 5, 2021: Lancet Oncology
https://read.qxmd.com/read/34237249/stereotactic-body-radiotherapy-plus-pembrolizumab-and-trametinib-versus-stereotactic-body-radiotherapy-plus-gemcitabine-for-locally-recurrent-pancreatic-cancer-after-surgical-resection-an-open-label-randomised-controlled-phase-2-trial
#15
Xiaofei Zhu, Yangsen Cao, Wenyu Liu, Xiaoping Ju, Xianzhi Zhao, Lingong Jiang, Yusheng Ye, Gang Jin, Huojun Zhang
BACKGROUND: There is paucity of investigations into immunotherapy or targeted therapy for postoperative locally recurrent pancreatic cancer. We aimed to assess the efficacy of stereotactic body radiotherapy (SBRT) plus pembrolizumab and trametinib in these patients. METHODS: In this open-label, randomised, controlled, phase 2 study, participants were recruited from Changhai Hospital affiliated to Naval Medical University, Shanghai, China. Eligible patients were aged 18 years or older with histologically confirmed pancreatic ductal adenocarcinoma characterised by mutant KRAS and positive immunohistochemical staining of PD-L1, Eastern Cooperative Oncology Group performance status of 0 or 1, and documented local recurrence after surgery followed by chemotherapy (mFOLFIRINOX or 5-fluorouracil)...
July 5, 2021: Lancet Oncology
https://read.qxmd.com/read/34224671/effect-of-general-practitioner-led-versus-surgeon-led-colon-cancer-survivorship-care-with-or-without-ehealth-support-on-quality-of-life-i-care-an-interim-analysis-of-1-year-results-of-a-randomised-controlled-trial
#16
Julien A M Vos, Laura A M Duineveld, Thijs Wieldraaijer, Jan Wind, Wim B Busschers, Edanur Sert, Pieter J Tanis, Irma M Verdonck-de Leeuw, Henk C P M van Weert, Kristel M van Asselt
BACKGROUND: Colon cancer is associated with an increased risk of physical and psychosocial morbidity, even after treatment. General practitioner (GP) care could be beneficial to help to reduce this morbidity. We aimed to assess quality of life (QOL) in patients who received GP-led survivorship care after treatment for colon cancer compared with those who received surgeon-led care. Furthermore, the effect of an eHealth app (Oncokompas) on QOL was assessed in both patient groups. METHODS: We did a pragmatic two-by-two factorial, open-label, randomised, controlled trial at eight hospitals in the Netherlands...
July 2, 2021: Lancet Oncology
https://read.qxmd.com/read/34224670/who-should-manage-post-treatment-care-for-patients-with-colon-cancer-surgeons-or-general-practitioners
#17
Eva Angenete
No abstract text is available yet for this article.
July 2, 2021: Lancet Oncology
https://read.qxmd.com/read/34217377/the-challenges-of-cancer-care-for-the-lqbtq-community
#18
Talha Khan Burki
No abstract text is available yet for this article.
July 1, 2021: Lancet Oncology
https://read.qxmd.com/read/34216541/the-international-collaboration-for-research-methods-development-in-oncology-credo-workshops-shaping-the-future-of-global-oncology-research
#19
REVIEW
Priya Ranganathan, Girish Chinnaswamy, Manju Sengar, Durga Gadgil, Shivakumar Thiagarajan, Balram Bhargava, Christopher M Booth, Marc Buyse, Sanjiv Chopra, Chris Frampton, Satish Gopal, Nick Grant, Mark Krailo, Ruth Langley, Prashant Mathur, Xavier Paoletti, Mahesh Parmar, Arnie Purushotham, Douglas Pyle, Preetha Rajaraman, Martin R Stockler, Richard Sullivan, Soumya Swaminathan, Ian Tannock, Edward Trimble, Rajendra A Badwe, C S Pramesh
Low-income and middle-income countries (LMICs) have a disproportionately high burden of cancer and cancer mortality. The unique barriers to optimum cancer care in these regions necessitate context-specific research. The conduct of research in LMICs has several challenges, not least of which is a paucity of formal training in research methods. Building capacity by training early career researchers is essential to improve research output and cancer outcomes in LMICs. The International Collaboration for Research methods Development in Oncology (CReDO) workshop is an initiative by the Tata Memorial Centre and the National Cancer Grid of India to address gaps in research training and increase capacity in oncology research...
June 30, 2021: Lancet Oncology
https://read.qxmd.com/read/34214495/neural-stem-cell-delivery-of-an-oncolytic-adenovirus-in-newly-diagnosed-malignant-glioma-a-first-in-human-phase-1-dose-escalation-trial
#20
Jawad Fares, Atique U Ahmed, Ilya V Ulasov, Adam M Sonabend, Jason Miska, Catalina Lee-Chang, Irina V Balyasnikova, James P Chandler, Jana Portnow, Matthew C Tate, Priya Kumthekar, Rimas V Lukas, Sean A Grimm, Ann K Adams, Charles D Hébert, Theresa V Strong, Christina Amidei, Victor A Arrieta, Markella Zannikou, Craig Horbinski, Hui Zhang, Kirsten Bell Burdett, David T Curiel, Sean Sachdev, Karen S Aboody, Roger Stupp, Maciej S Lesniak
BACKGROUND: Malignant glioma is the most common and lethal primary brain tumour, with dismal survival rates and no effective treatment. We examined the safety and activity of NSC-CRAd-S-pk7, an engineered oncolytic adenovirus delivered by neural stem cells (NSCs), in patients with newly diagnosed high-grade glioma. METHODS: This was a first-in-human, open-label, phase 1, dose-escalation trial done to determine the maximal tolerated dose of NSC-CRAd-S-pk7, following a 3 + 3 design...
June 29, 2021: Lancet Oncology
journal
journal
20189
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"